GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations

NCT02082496 · Completed

Last updated 2026-05-28

This clinical trial is testing how a diabetes medication called GLP-1 receptor agonist affects insulin levels in people with obesity who have specific genetic mutations compared to those without the mutations.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) basic-science study

Participants 50 people

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2014-06 · est. completion 2019-04

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT02082496 ↗

Description as written by the study sponsor.

The obesity epidemic is attributable to dietary and behavioral trends acting on a person's genetic makeup to determine body mass and susceptibility to obesity-related diseases. Furthermore, common forms of obesity have a strong hereditary component and many genetic pathways that contribute to obesity have already ben identified. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that potentiates glucose-stimulated insulin secretion. However, GLP-1 also acts as an appetite-inhibiting hormone affecting the appetite center in the hypothalamus. Today, GLP-1 receptor agonists are available for the treatment of type 2 diabetes, and their treatment potential in obesity is an area of active research. The aim of this study is to explore if the appetite inhibiting effect of GLP-1 is intact in people diagnosed with obesity causing genetic disorders and to investigate the physiological role of GLP-1 on food intake and appetite regulation in this group.

Treatments tested

Liraglutide also known as Victoza, Novo Nordisk A/S in DK-2880 Bagsvaerd, Serial number:76477425, International code name: 005, US Class Codes: 006, 018, 044, 046, 051, 052 Drug

S.c. liraglutide 3.0mg once daily

Main thing measured	Difference in insulin levels in reponse to GLP-1 RA treatment in obese genetic mutation carriers vs obese controls
Sponsor	University of Copenhagen
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02082496 ↗